Warning: The NCBI web site requires JavaScript to function. more...
Clinically immune hosts as a refuge for drug-sensitive malaria parasites.
Klein EY, Smith DL, Boni MF, Laxminarayan R.
Malar J. 2008 Apr 25;7:67.
Related citations
[Mechanisms and dynamics of drug resistance in Plasmodium falciparum].
Le Bras J.
Bull Soc Pathol Exot. 1999 Sep-Oct;92(4):236-41. Review. French.
Spread of anti-malarial drug resistance: mathematical model with implications for ACT drug policies.
Pongtavornpinyo W, Yeung S, Hastings IM, Dondorp AM, Day NP, White NJ.
Malar J. 2008 Nov 2;7:229.
Potential impact of intermittent preventive treatment (IPT) on spread of drug-resistant malaria.
O'Meara WP, Smith DL, McKenzie FE.
PLoS Med. 2006 May;3(5):e141. Epub 2006 Apr 4.
Optimally timing primaquine treatment to reduce Plasmodium falciparum transmission in low endemicity Thai-Myanmar border populations.
Lawpoolsri S, Klein EY, Singhasivanon P, Yimsamran S, Thanyavanich N, Maneeboonyang W, Hungerford LL, Maguire JH, Smith DL.
Malar J. 2009 Jul 15;8:159.
The impact of HIV-1 on the malaria parasite biomass in adults in sub-Saharan Africa contributes to the emergence of antimalarial drug resistance.
Van Geertruyden JP, Menten J, Colebunders R, Korenromp E, D'Alessandro U.
Malar J. 2008 Jul 22;7:134.
Population biology and antimalarial resistance: The transmission of antimalarial drug resistance in Plasmodium falciparum.
Barnes KI, White NJ.
Acta Trop. 2005 Jun;94(3):230-40. Review.
A model for the coevolution of immunity and immune evasion in vector-borne diseases with implications for the epidemiology of malaria.
Koella JC, Boëte C.
Am Nat. 2003 May;161(5):698-707. Epub 2003 Mar 21.
Intensity of malaria transmission and the evolution of drug resistance.
Hastings IM, Watkins WM.
Acta Trop. 2005 Jun;94(3):218-29. Epub 2005 Apr 19. Review.
Role of the bovine immune system and genome in resistance to gastrointestinal nematodes.
Gasbarre LC, Leighton EA, Sonstegard T.
Vet Parasitol. 2001 Jul 12;98(1-3):51-64. Review.
The mechanisms of resistance to antimalarial drugs in Plasmodium falciparum.
Le Bras J, Durand R.
Fundam Clin Pharmacol. 2003 Apr;17(2):147-53. Review.
What should vaccine developers ask? Simulation of the effectiveness of malaria vaccines.
Penny MA, Maire N, Studer A, Schapira A, Smith TA.
PLoS One. 2008 Sep 11;3(9):e3193.
Determination of the processes driving the acquisition of immunity to malaria using a mathematical transmission model.
Filipe JA, Riley EM, Drakeley CJ, Sutherland CJ, Ghani AC.
PLoS Comput Biol. 2007 Dec;3(12):e255. Epub 2007 Nov 14.
The consequences of reducing transmission of Plasmodium falciparum in Africa.
Snow RW, Marsh K.
Adv Parasitol. 2002;52:235-64. Review.
Epidemiological models for the spread of anti-malarial resistance.
Koella JC, Antia R.
Malar J. 2003 Feb 19;2:3. Epub 2003 Feb 19.
The evolution of multiple drug resistance in malaria parasites.
Mackinnon MJ, Hastings IM.
Trans R Soc Trop Med Hyg. 1998 Mar-Apr;92(2):188-95. Review.
The de novo selection of drug-resistant malaria parasites.
White NJ, Pongtavornpinyo W.
Proc Biol Sci. 2003 Mar 7;270(1514):545-54.
Environmental, pharmacological and genetic influences on the spread of drug-resistant malaria.
Antao T, Hastings IM.
Proc Biol Sci. 2011 Jun 7;278(1712):1705-12. Epub 2010 Nov 17.
Modelling the impact of artemisinin combination therapy and long-acting treatments on malaria transmission intensity.
Okell LC, Drakeley CJ, Bousema T, Whitty CJ, Ghani AC.
PLoS Med. 2008 Nov 25;5(11):e226; discussion e226.
Potential impact of host immunity on malaria treatment outcome in Tanzanian children infected with Plasmodium falciparum.
Enevold A, Nkya WM, Theisen M, Vestergaard LS, Jensen AT, Staalsoe T, Theander TG, Bygbjerg IC, Alifrangis M.
Malar J. 2007 Nov 16;6:153.
Filter your results:
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on